Market Research Report :Oncology Pharmaceuticals Market in India 2012
Market Research Report : Oncology pharmaceuticals market in india 2014 - Sample
-
Upload
netscribes-inc -
Category
Business
-
view
623 -
download
0
description
Transcript of Market Research Report : Oncology pharmaceuticals market in india 2014 - Sample
1
Oncology Pharmaceuticals Market-India
August 2011
Oncology Pharmaceuticals Market in India
September 2014
2 ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
Drivers: Increasing number of cancer cases Changes in the treatment scenario Development of alternative cancer therapies Increase in cancer insurances Increase in FDI
Drug regulation and patents
Oncology pharmaceuticals market in India is valued at INR x bn in 20— Fourth largest in volume, eighth largest in value in the world market Market is expected to grow at a CAGR of y% from20-----
Challenges: Increased competition Drug patents problem Drug Portfolio management
Government Initiatives
Reforms in tax structure Reduction in drug prices Public –Private Partnership (PPP) programmes Drug control programmes
Phases of clinical trial Approval and licensing of drugs Patents
Competition
Highly fragmented market with large number of players Major public players in the market include Company A,Company B, Company C, Company D,
Company E, Company F, Company G, Company H, Company I, Company J Major private companies include Company K, Company L, Company M
Drivers and Challenges
Market
Executive Summary
3
•Macro-Economic Indicators
•Introduction
•Market Overview
•Export-Import
•Market Value Chain
•Drivers & Challenges
•Government Initiatives
•Regulations
•Competitive Landscape
•Recent Developments
•Strategic Recommendations
•Appendix
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
4
Economic Indicators (1/3)
11
12
13
14
15
INR tn
Q4
c4
b4
a4
Q3
c3 b3
a3
Q2
d2 c2
b2
a2
Q1
d1 c1
b1
a1
2013-14 2012-13 2011-12 2010-11
GDP at Factor Cost: Quarterly
Inflation Rate: Monthly
-2
-1
0
1
2
q
Aug 2013 - Sep 2013
r
Sep 2013 - Oct 2013 Jul 2013 - Aug 2013
p
Nov 2013 - Dec 2013
t
Oct 2013 - Nov 2013
%
s
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
5
Indian oncology pharma market has grown enormously over the last few years
•Fourth largest in volume, eighth largest in value in the world market
•Expected to reach INR y bn in 20--
•Cancer is the second largest cause of death in the country
•According to the National Cancer Registry Program (NCRP) there are z mn cancer patients at any point of time
•There occurs X cancer related deaths each year
•Oral and lung cancer are the most common in males, while in females, cervical, followed by breast and ovarian cancer are the most common
•Availibilty of xx oncologists per yy people in India
Indian market-overview Market size
Source:
Increase in Cancer Cases
0
200
400
600
800
1,000
1,200
In ‘000
20--
x
20--e
n%
y
0
10
20
30
40
50
INR unit
20-- 20--e 20--e 20--e 20--e 20--e 20--
m% g
f e
d c b a
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
6
A huge volume of cancer drugs is exported to many countries…
• Highly fragmented market with many domestic
manufacturers lead to huge volume of exports
• India currently exports to more than 115 countries
• Between 20-- - 20-- and 20-- - 20-- the value of export
of oncology pharmaceuticals rose by m%
• Country A accounted for the highest exports in 20-- -
20-- while Country B ranked highest in 20-- - 20--
Exports of Oncological Pharmaceuticals Total Exports
Exports – Region wise (20-- - 20--) Exports – Region wise (20-- - 20--)
0
1,000
2,000
3,000
4,000
INR units
20– to 20--
e2
20–to 20--
e1
P%
e5
20– to 20--
e4
20– to 20--
e3
20– to 20--
Note: All figures are for financial year Source: Ministry of Commerce: Export-Import Data Bank
D1% C1%
E1%
G1%
B1%
A1%
E2%
G2%
D2%
A2%
B2%
F2%
Country F
Country D
Country E
Country G
Country C
Country B
Country A
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
7
Drivers & Challenges - Summary
Drivers
Increasing number of cancer cases
Changes in the treatment scenario
Development of alternative cancer therapies
Increase in cancer insurances
Increase in the amount of FDI
Challenges
Increased competition
Drug patent problems
Drug portfolio management
Lack of affordability
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
8
Government initiatives
Reforms in tax structure
Public-Private-partnership
(PPP) projects
Cancer control programmes
Reduction in drug prices
Government Initiative
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
9
SAMPLE Porter’s Five Forces Analysis
Competitive Rivalry • Texttext texttext texttext texttext
texttext texttext texttext • Texttext texttext texttext texttext
texttext texttext texttext
Bargaining Power of Buyers • Texttext texttext texttext
texttext texttext texttext texttext
• Texttext texttext texttext texttext texttext texttext texttext
Threat of New Entrants • Texttext texttext texttext texttext
texttext texttext texttext • Texttext texttext texttext texttext
texttext texttext texttext
Impact Low to
Medium
Impact Medium to
High
Impact High
Bargaining Power of Suppliers • Texttext texttext texttext texttext
texttext texttext texttext • Texttext texttext texttext texttext
texttext texttext texttext • Texttext texttext texttext texttext
texttext texttext texttext
Impact Low to
Medium
Threat of Substitutes • Texttext texttext texttext texttext
texttext texttext texttext • Texttext texttext texttext texttext
texttext texttext texttext
Impact Low
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
10
SAMPLE Competitive Benchmarking (1/5)
Public Trading Comparables (FY 2013) – Top 3 Companies
Company A Company B Company C
Market Capitalization (INR mn) Value Value
Value
Share Price (INR) Value Value Value
EV/EBITDA (INR mn) Value Value Value
EV/Revenue (INR mn) Value Value Value
PE Ratio Value Value Value
Note: Top 3 Public companies based on the Market Capitalization, Share Price and PE ratio is as of 18/05/2014
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
11
SAMPLE Key Ratios of Top 3 Companies – Operational Basis (FY 20--) (1/3)
Competitive Benchmarking (1/4)
-30
-20
-10
0
10
%
Player C
q3
Player B
q2 p2
Player A
q1 p1
Net Margin Operating Margin
• X
• X
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
12
Public: Domestic Company – Company A (1/3)
Key People
Products and Services
Company Information Offices and Centres – India
Corporate Address X Road
Bangalore
Tel No. +91 xx xxxxx xxxxx
Fax No. +91 xx xxxxx xxxxx
Website www.ppp.com
Year of
Incorporation 19--
Ticker Symbol xxxxxx
Stock Exchange NNN
Name Designation
Person M Founder
Person N CFO
Person O Head
Person Q President
City A Products and Services Head Office
Source:
Category Products/Services
Pharmaceutical CVD, oncology, CNS, respiratory, dermatology, orthopedics, nutritional, urology, anti-infectives
Molecule Development
Infectious diseases, metabolic diseases, inflammatory/respiratory diseases, and oncology
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
13
Source:
Key Ratios
Financial Summary
Public: Domestic Company – Company B (2/3)
• The company incurred a net loss of INR xx mn in FY 20--, as compared to net profit of INR yy mn in FY 20--
• The company reported total income of INR xx bn in FY 20--, registering an increase of yy per cent over FY 20--
• The company earned an operating margin of x per cent in FY 20-- a decrease of y percentage points over FY 20--
• The company reported debt to equity ratio of x in FY 20--, an increase of y per cent over FY 20--
Financial Summary
Profit / Loss
Revenue Profit
INR mn
p
n
0
-m
Revenue INR mn
0
20--
t p
20--
s
o
20--
r
n
20--
q
m
10,000
5,000
Indicators Present Value
Market Capitalization (INR) X units
Total Enterprise Value (INR) Y units
EPS (INR) Z units
PE Ratio (Absolute) A
Particulars y-o-y change 20-- 20-- 20-- 20--
Profitability Ratios Operating Margin
Net Margin
Profit Before Tax Margin
Return on Equity
Return on Capital Employed
Return on Working Capital
Return on Assets
Return on Fixed Assets
Cost Ratios Operating costs (% of Sales)
Administration costs (% of Sales)
Interest costs (% of Sales)
Liquidity Ratios Current Ratio
Cash Ratio
Leverage Ratios Debt to Equity Ratio
Debt to Capital Ratio
Interest Coverage Ratio
Efficiency Ratios Fixed Asset Turnover
Asset Turnover
Current Asset Turnover
Working Capital Turnover
Capital Employed Turnover
Improved Decline
Financial Snapshot
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
14
Public: Domestic Company – Company C (3/3)
y
x
20--
z y
x
20--
z y
x
20--
z y
x
20--
z
o n m
Key Business Segments
20--
z
y
x
20--
z
y
x
20--
z
y
x
20--
z
y
x
x y z
Key Geographic Segments
Source:
Key Recent Developments
Description News
Overview • Company A is an integrated research based company that produces a wide range of generic medicines
• Serves customers in over 100 countries with manufacturing facilities in several countries
Oncology Pharmaceuticals • Products include include Product 1 and Product 2
Key Initiatives • Is making consistent effort for continual improvement in rural areas with respect to accessibility of
medicines
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
15
Thank you for the attention
About Netscribes, Inc. Netscribes, Inc. is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes, Inc. is a one-stop shop designed to fulfil clients’ profitability and growth objectives.
Oncology Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Series. For any queries or customized research requirements, contact us at:
Disclaimer: This report is published for general information only. Although high standards have been used in the preparation, “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes and prior permission is required for guidelines on reproduction.
Phone: +91 22 4098 7600 E-Mail: [email protected]
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT